CAR T-Cell Therapy for Large B-Cell Lymphoma
Practical information for the advanced practitioner on a revolutionary cancer treatment
This supplement to JADPRO, developed in partnership with Nexus Global Group Science LLC, aims to provide practical information to advanced practitioners on a number of considerations when implementing CAR T-cell therapy. It is sponsored by Kite, a Gilead Company.
Editorial
CAR T-Cell Therapy for Large B-Cell Lymphoma
Maritza C. Alencar, DNP, MBA, APRN-BC, BMTCN®
Read MoreReview Article
Anti-CD19 CAR T-Cell Therapy for Adult Patients With Refractory Large B-Cell Lymphoma
Kathleen McDermott, RN, BSN, OCN®, BMTCN®, and Lauren Spendley, AGNP, MSN, AOCN®Read MoreReview Article
CAR T-Cell Therapy: Adverse Events and Management
Sherry Adkins, RN, MSN, ANP-CRead MoreReview Article
Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy
Alix Beaupierre, RN, BSN, OCN®, Nicole Kahle, MS, RN, OCN®, BMTCN®, Rachel Lundberg, PA-C, MPAS, and Amy Patterson, MSN, APRN, AOCNS®, BMTCN®Read More